111In-aγH2AX-TAT

111In-aγH2AX-TAT is a novel radioimmunoconjugate developed by the University of Oxford for the noninvasive imaging and therapeutic amplification of DNA damage in cancer. It consists of a monoclonal antibody targeting phosphorylated histone H2AX (γH2AX)—a key biomarker of DNA double-strand breaks—conjugated to the cell-penetrating peptide TAT (transactivator of transcription) to facilitate nuclear localization, and radiolabeled with the Auger electron-emitting radionuclide Indium-111 (111In) via a DTPA chelator. Primarily utilized as a SPECT imaging agent and biodosimeter to monitor tumor response to radiotherapy or chemotherapy, 111In-aγH2AX-TAT also exhibits therapeutic potential; when administered at high specific activity, the localized emission of Auger electrons in close proximity to the host DNA amplifies double-strand breaks and enhances treatment-related cytotoxicity.

Other names

111In-DTPA-anti-γH2AX-TAT111In-anti-gH2AX-TAT111In-anti-γH2AX-TAT111In-αγH2AX-TAT[111In]-DTPA-anti-γH2AX-Tat